What we know about long-acting injectable antipsychotics can help innovate HIV care
Date:
05/01/2021
Topics:
Citation:
Kates OS. What We Know About Long-acting Injectable Antipsychotics Can Help Innovate HIV Care. AMA J Ethics. 2021 May 1;23(5):E405-409. doi: 10.1001/amajethics.2021.405. PMID: 34038349.
Abstract
Long-acting injectable antiretroviral therapy (LA-ART) is a powerful new addition to the treatments available for patients living with HIV, but broad acceptance and uptake could be compromised by what we know about patients' and clinicians' experiences with long-acting injectable antipsychotics (LAI-APs). Treatment of stigmatized conditions, such as psychiatric illness or HIV, using long-acting injection is ethically fraught with patients' fear of coercion and forced administration. Strategies that emphasize patient-centered, patient-directed care and that place limits on when LAI can be administered forcibly can help promote LA-ART's acceptance and use.